AptarGroup, Inc. (ATR) Stock: Price, Forecast & Analyst Target
AptarGroup, Inc. (ATR) — MoonshotScore 76/100 (Strong band), calculated Oct 5, 2026. Price $118.96 (-0.79%), as of the Oct 5, 2026 trading session; market cap $7.59B. Expected results Oct 29, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 38.48× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Oct 29, 2026
AptarGroup, Inc. · ATR · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: AptarGroup supplies the pumps, valves, closures, seals and elastomer components that control how medicines, beauty products, household goods, food and beverages are dispensed. Its prospects depend on whether growth in pharmaceutical components and restored Beauty plus Home pricing can support earnings while capital investment and debt continue to absorb financial capacity.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · AptarGroup (ATR)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, at a cheap price, though the balance sheet is only decent. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue $1.03B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 7 of 8
- Altman Z 3.88 · Piotroski F 6
Helping: business quality, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 75 | Strong | |
| 76 | Strong | |
| 76 | Strong | |
| 76 | Strong | |
| 76 | Strong | |
| 76 | Strong |
The score was 76 in the stored Oct 4, 2026 snapshot and remains 76 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $118.96 | |
| Change on the day | -0.79% | |
| 52-week range | $103.23–$146.91 | |
| Market capitalisation | $7.59B | |
| Price / earnings (trailing) | 21.41 | |
| Shares traded on the day | 5.2K | |
| Beta (volatility vs the S&P 500) | 0.38 | |
| Dividends per share (last 12 months) | $1.92 | |
| Dividend yield (last 12 months) | 1.60% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We anticipate third quarter adjusted earnings per share to be in the range of $1.45 to $1.53 This assumes an effective tax rate range of 22.5% to 24.5%.
Vanessa Kanu · Statement from
For full-year 2026, we continue to expect capital investments to be in the range of $260 million to $280 million and depreciation and amortisation expense to be between $310 million and $320 million.
Vanessa Kanu · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for AptarGroup (ATR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 28, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 28, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 28, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ATR film — every key number, told as a short cinematic story
~2 min · open the film
What is AptarGroup (ATR), and what does it report?
Short answer · as of
Aptar does not sell medicines, cosmetics or beverages.
Research dated 2026-09-13.
Aptar does not sell medicines, cosmetics or beverages. It sells the delivery and sealing hardware used inside those products, including nasal pumps, inhaler valves, injectable packaging, beauty pumps, aerosol valves, flow-control parts and closures. Demand therefore follows customer production volumes, product mix and the value of the component supplied.
Reporting follows Pharma, Beauty plus Home, and Food plus Beverage. Pharma includes drug-delivery and injectable components as well as active material science, while the consumer-facing businesses supply dispensing and closure systems for beauty, personal care, household, food and beverage customers. Among the disclosed segment totals, Pharma contributes more revenue than Beauty.
What do the latest results show for AptarGroup (ATR)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.03B.
Research dated 2026-09-13.
The latest period extended the upward sales progression: revenue advanced from the prior period and from the comparable period. Gross profit, operating profit and net income also improved sequentially, yet each remained below its comparable-period level. Reported revenue and earnings cleared consensus in the latest release.
Management attributed part of the Beauty margin pressure to delayed pricing pass-through and said that delay should be resolved in the following period. That explanation creates a direct test: Beauty profitability should improve if customer pricing catches up, even without relying on a major change in sales volume.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.03B Jun 30, 2026
- Latest quarter · R&D
- $157.74M Jun 30, 2026
- Latest quarter · SG&A
- $167.56M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $128.14M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $1.03B | $157.74M | $167.56M | $128.14M |
| Mar 31, 2026 | $982.87M | $167.60M | $167.56M | $108.63M |
| Dec 31, 2025 | $962.74M | Not available | $150.95M | $110.69M |
| Sep 30, 2025 | $961.13M | Not available | $148.76M | $139.09M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.03B Jul 30, 2026
- Latest report · revenue estimate
- $1.01B Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $1.03B | $1.01B | $1.4200 | $1.3500 |
| Apr 30, 2026 | $982.87M | $955.95M | $1.1900 | $1.1500 |
| Feb 5, 2026 | $962.74M | $878.58M | $1.2500 | $1.2400 |
| Oct 30, 2025 | $961.13M | $880.25M | $1.6200 | $1.5700 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.03B | $88M | $1.36 (diluted) |
| Q1 FY2026 | $983M | $73M | $1.12 (diluted) |
| Q4 FY2025 | $963M | $74M | $1.13 (diluted) |
| Q3 FY2025 | $961M | $128M | $1.92 (diluted) |
What are the financial strengths and risks for AptarGroup (ATR)?
Short answer
Cash and short-term investments were $197.27M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $103.49M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow remained positive throughout the reported series and exceeded capital spending in every period shown. The residual cash generation is meaningful, but recent operating cash flow has softened from earlier highs while management continues to plan substantial investment.
Cash and short-term investments declined across the reported window, and total debt remains far above liquid resources even after including long-term investments. Near-term liquidity ratios remain above parity, but this is not a net-cash balance sheet. Regular dividend payments add a recurring use of cash.
The financial tension is specific to Aptar's model: capital spending must support manufacturing capacity and specialized components, while delayed price recovery can compress Beauty margins before customer pricing catches up. Persistent cash erosion alongside heavy investment or another pricing lag would weaken the case.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $103.49M Jun 30, 2026
- Previous quarter · operating cash flow
- $118.69M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $103.49M | −$57.56M |
| Mar 31, 2026 | $118.69M | −$65.40M |
| Dec 31, 2025 | $183.69M | −$86.82M |
| Sep 30, 2025 | $177.61M | −$63.31M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at AptarGroup (ATR)?
Short answer · as of
The next earnings report is expected on Oct 29, 2026.
Research dated 2026-09-13.
Beauty plus Home margin is the immediate operating checkpoint. Improvement would support management's claim that delayed pricing was temporary; continued pressure would point to weaker pass-through or a broader profitability problem. Gross profit and operating profit should therefore be read alongside revenue rather than treated as automatic consequences of sales growth.
Cash conversion is the other checkpoint. Compare operating cash flow with capital spending, then watch whether cash and short-term investments stabilize against the debt load. The scheduled earnings release and management's earnings outlook provide the next formal tests, while longer-range consensus assumes continued revenue and earnings expansion that still needs confirmation in reported results.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We anticipate third quarter adjusted earnings per share to be in the range of $1.45 to $1.53 This assumes an effective tax rate range of 22.5% to 24.5%.
Vanessa Kanu ·
For full-year 2026, we continue to expect capital investments to be in the range of $260 million to $280 million and depreciation and amortisation expense to be between $310 million and $320 million.
Vanessa Kanu ·
So every segment passed through a beauty, but we had a bit of a lag, which was a bit of a you know, a detriment. it is probably about you know, 80, 90 basis points of margin on beauty impact of that delayed pass through in the quarter, and we expect that to be resolved in Q3.
Vanessa Kanu ·
How does AptarGroup compare with its peers?
Short answer
AptarGroup's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Aptar is broader than its healthcare classification suggests. Pharma is the larger disclosed segment, but the company also sells beauty pumps, household dispensers, food closures and beverage flow-control components. This creates exposure to regulated drug-delivery demand and consumer packaging demand within the same manufacturer.
Compared with a drugmaker, Aptar's revenue comes from components incorporated into customer products rather than from therapeutic ownership. Compared with a beauty-focused dispenser supplier, its nasal pumps, inhaler valves and injectable elastomer packaging add a pharmaceutical component base. The trade-off is that specialized Pharma demand and consumer-facing pricing cycles can pull profitability in different directions.
| Company | Price | Market value | Score |
|---|---|---|---|
| $109.86 Oct 2, 2026 | $13.0B | 97 5-pillar Oct 5, 2026 | |
| $75.60 Oct 2, 2026 | $10.2B | 96 5-pillar Oct 5, 2026 | |
| $104.68 Oct 2, 2026 | $4.76B | 87 5-pillar Oct 5, 2026 | |
| $85.37 Oct 2, 2026 | $5.10B | 85 5-pillar Oct 5, 2026 | |
| $181.70 Oct 2, 2026 | $10.3B | 82 5-pillar Oct 5, 2026 | |
| $20.20 Oct 2, 2026 | $5.51B | 80 5-pillar Oct 5, 2026 | |
| AptarGroup (ATR) — this page | $118.96 | $7.59B | 76 |
| $84.88 Oct 2, 2026 | $9.67B | 75 5-pillar Oct 5, 2026 | |
| $189.54 Oct 2, 2026 | $9.89B | 70 5-pillar Oct 5, 2026 | |
| $159.38 Oct 2, 2026 | $3.98B | 66 5-pillar Oct 5, 2026 | |
| $15.34 Oct 2, 2026 | $10.4B | 56 5-pillar Oct 5, 2026 | |
| $124.12 Oct 2, 2026 | $5.49B | 55 5-pillar Oct 5, 2026 | |
| $23.49 Oct 2, 2026 | $12.1B | 54 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $160.00 – $160.00
- Consensus target
- $160.00
- Median target
- $160.00
Consensus record · Captured .
Measured against a quoted price of $118.96 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 2, 2026
- Transactions
- 55
- Identified insiders
- 18
- Purchases
- 0
- Sales
- 15
- Other transactions
- 40
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 97.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 92.6% Prior to period end Jun 30, 2026
- Reporting holders
- 562 Period end Jun 30, 2026
- Previous quarter · holders
- 549 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 6,137,894 |
| State Farm Mutual Automobile Insurance Co | 4,744,564 |
| Vanguard Portfolio Management LLC | 3,638,724 |
| Morgan Stanley | 3,523,908 |
| Vanguard Capital Management LLC | 2,893,751 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about AptarGroup (ATR)?
What Investors Ask About AptarGroup (ATR) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What does Aptar Pharma supply to drugmakers?
Aptar Pharma supplies nasal pumps, metered-dose inhaler valves, elastomer packaging for injectables and active material science solutions. Its economics come from the delivery and protection components used with therapies, not from ownership of the drugs themselves.
Why is Beauty plus Home pricing important for Aptar?
A lag in passing costs through to Beauty customers reduced segment margin, according to management. Margin recovery would indicate that customer pricing has caught up; continued pressure would challenge that explanation.
What is Aptar developing with PureCycle?
Aptar is working with PureCycle to integrate ultra-pure recycled polypropylene into advanced dispensing applications. The effort links recycled material inputs with Aptar's core dispensing designs.
Does Aptar generate cash after capital spending?
Operating cash flow exceeded capital spending throughout the reported series, leaving positive residual cash generation. Even so, cash and short-term investments declined across the window, while debt remained larger than liquid resources.
What is the ATR stock price today?
The last price recorded on this page for AptarGroup, Inc. (ATR) is $118.96, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ATR price target?
The analyst consensus price target for AptarGroup, Inc. (ATR) is $160.00 (range $160.00 to $160.00, median $160.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does ATR pay a dividend?
Yes. AptarGroup, Inc. (ATR) shows a trailing 12-month dividend yield of 1.60%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (83 figures)
The 83 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Vanessa Kanu (Jul 31, 2026): We anticipate third quarter adjusted earnings per share to be in the range of $1.45 to $1.53 This assumes an effective tax rate range of 22.5% to 24.5%. Vanessa Kanu (Jul 31, 2026): For full-year 2026, we continue to expect capital investments to be in the range of $260 million to $280 million and depreciation and amortisation expense to be between $310 million and $320 million. Vanessa Kanu (Jul 31, 2026): So every segment passed through a beauty, but we had a bit of a lag, which was a bit of a you know, a detriment. it is probably about you know, 80, 90 basis points of margin on beauty impact of that delayed pass through in the quarter, and we expect that to be resolved in Q3. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 265 Exchange Drive, Suite 301, Crystal Lake, IL, 60014 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "265 Exchange Drive, Crystal Lake, IL, 60014, US". |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 29, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $118.96 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T13:44:41.769Z. | |
px.change | Change on the day | -0.79% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $7.59B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T13:44:07.000Z. Captured from FMP at 2026-10-05T13:44:36.588Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.95 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $1.03B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $103.23–$146.91 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 21.41 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5.2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.38 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Gael Touya | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 14,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $3.23B, net result $244.10M; FY2022 revenue $3.32B, net result $239.29M; FY2023 revenue $3.49B, net result $284.49M; FY2024 revenue $3.58B, net result $374.54M; FY2025 revenue $3.78B, net result $392.79M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Beauty Segment $1.31B · Pharma Segment $1.74B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 28.3% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $1.03B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $157.74M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $167.56M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $128.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $982.87M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $167.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $167.56M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $108.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $962.74M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $150.95M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $110.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $961.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $148.76M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $139.09M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-30.revenue_actual | Revenue · reported — report date 2026-07-30 | $1.03B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.revenue_estimated | Revenue · estimate — report date 2026-07-30 | $1.01B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_actual | EPS · reported — report date 2026-07-30 | $1.4200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_estimated | EPS · estimate — report date 2026-07-30 | $1.3500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_actual | Revenue · reported — report date 2026-04-30 | $982.87M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_estimated | Revenue · estimate — report date 2026-04-30 | $955.95M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_actual | EPS · reported — report date 2026-04-30 | $1.1900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_estimated | EPS · estimate — report date 2026-04-30 | $1.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_actual | Revenue · reported — report date 2026-02-05 | $962.74M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_estimated | Revenue · estimate — report date 2026-02-05 | $878.58M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_actual | EPS · reported — report date 2026-02-05 | $1.2500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_estimated | EPS · estimate — report date 2026-02-05 | $1.2400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_actual | Revenue · reported — report date 2025-10-30 | $961.13M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_estimated | Revenue · estimate — report date 2025-10-30 | $880.25M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_actual | EPS · reported — report date 2025-10-30 | $1.6200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_estimated | EPS · estimate — report date 2025-10-30 | $1.5700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $197.27M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $103.49M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $134.75M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $1.43B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 2.91× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $103.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $118.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$57.56M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$65.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $183.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$86.82M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $177.61M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$63.31M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $160.00 – $160.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $160.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $160.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 55 transactions · 0 purchases, 15 sales, 40 other transactions · 18 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 2, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 97.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 92.6% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 562 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 549 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 6,137,894 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | State Farm Mutual Automobile Insurance Co — shares in provider snapshot | 4,744,564 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 3,638,724 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Morgan Stanley — shares in provider snapshot | 3,523,908 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Capital Management LLC — shares in provider snapshot | 2,893,751 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.88 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 38.48× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $197.27M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.92 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 1.60% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-30.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.03B) with the recorded estimate ($1.01B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-30.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.4200) with the recorded estimate ($1.3500) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 76 of 100 · Strong · pillars 81 / 57 / 69 / 75 / 63 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 76 (stored snapshot Oct 4, 2026) → 76 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-30.revenue_actual,earn.history.depth.2026-07-30.revenue_estimated,earn.history.depth.2026-07-30.revenue_actual.comparison,earn.history.depth.2026-07-30.eps_actual.comparison,earn.history.depth.2026-07-30.eps_actual,earn.history.depth.2026-07-30.eps_estimated,earn.history.depth.2026-04-30.revenue_actual,earn.history.depth.2026-04-30.revenue_estimated,earn.history.depth.2026-04-30.eps_actual,earn.history.depth.2026-04-30.eps_estimated,earn.history.depth.2026-02-05.revenue_actual,earn.history.depth.2026-02-05.revenue_estimated,earn.history.depth.2026-02-05.eps_actual,earn.history.depth.2026-02-05.eps_estimated,earn.history.depth.2025-10-30.revenue_actual,earn.history.depth.2025-10-30.revenue_estimated,earn.history.depth.2025-10-30.eps_actual,earn.history.depth.2025-10-30.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | APTARGROUP, INC. Our market-data provider lists the name as "AptarGroup, Inc."; the filer's own record is used here. | 2026-02-06 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-06 |
| Business description | AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Beauty Segment: $1.31B; Pharma Segment: $1.74B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $1.43B; Liquidity basis: cash and short-term investments; Total liabilities: $2.46B; Cash and short-term investments: $197.27M; Cash and investments: $332.00M; Long-term investments: $134.75M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Management outlook — dated call excerpts | Captured record · 3 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-31 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Instruments & Supplies The company's SEC filings classify it under SIC 3089 — Plastics Products, NEC. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-30 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-07-31 | OFFICIAL | SEC EDGAR filer submissions | |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $332.00M; Cash and short-term investments: $197.30M; Long-term investments: $134.80M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $197.30M; Decline: $130.60M; Opening balance: $327.90M; Average change per period: $18.70M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$1.23B; Total debt: $1.43B; Cash and investments: $197.30M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.1; Current ratio: 1.61; Debt to equity: 0.54; Net margin: 9.2%; Gross margin: 28.3%; Operating margin: 12.4%; Return on assets: 7.1%; Return on equity: 13.5% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 3.95; Piotroski F-score: 6 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-07-30 | FMP | Financial Modeling Prep (FMP) dividend history |
| Dividends per share, last 12 months (split-adjusted) | $1.92 Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-09-13, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | 2026-07-30 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history |
| Next earnings report | Date: 2026-10-29; EPS estimate: $1.46 per share; Revenue estimate: $982.81M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.